Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
Saved in:
| Title: | Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. |
|---|---|
| Authors: | Fong Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington, USA., Dang L; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Zhang B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Fintzi J; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Chen S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Wang J; Frederick National Laboratory for Cancer Research, Clinical Monitoring Research Program Directorate, Frederick, Maryland, USA., Rouphael NG; Hope Clinic, Department of Medicine, Division of Infectious Diseases, Emory University, Decatur, Georgia, USA., Branche AR; Vaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA., Diemert DJ; George Washington Vaccine Research Unit, George Washington University, Washington, District of Columbia, USA., Falsey AR; Vaccine and Treatment Evaluation Unit, University of Rochester, Rochester, New York, USA., Losada C; Hope Clinic, Department of Medicine, Division of Infectious Diseases, Emory University, Decatur, Georgia, USA., Baden LR; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Frey SE; Center for Vaccine Development, Saint Louis University, Saint Louis, Missouri, USA., Whitaker JA; Department of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA., Little SJ; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA., Kamidani S; Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.; Department of Pediatrics, Emory University, Atlanta, Georgia, USA., Walter EB; Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA., Novak RM; Project WISH, University of Illinois at Chicago, Chicago, Illinois, USA., Rupp R; Department of Pediatrics, University of Texas Medical Branch, Galveston, Texas, USA., Jackson LA; Department of Internal Medicine, Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Magaret CA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Molitor C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Borate B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Babu TM; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington, USA., Kottkamp AC; Vaccine and Treatment Evaluation Unit, Manhattan Research Clinic, New York University Grossman School of Medicine, New York, New York, USA., Luetkemeyer AF; Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco, California, USA., Immergluck LC; Clinical Research Center, Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA., Presti RM; Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA., Bäcker M; Vaccine and Treatment Evaluation Unit, Long Island Research Clinic, New York University, Long Island School of Medicine, Mineola, New York, USA., Winokur PL; Department of Medicine, University of Iowa College of Medicine, Iowa City, Iowa, USA., Mahgoub SM; Howard University College of Medicine, Howard University Hospital, Washington, District of Columbia, USA., Goepfert PA; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA., Fusco DN; Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA., Atmar RL; Department of Molecular Virology and Microbiology and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA., Posavad CM; Infectious Diseases Clinical Research Consortium (IDCRC) Laboratory Operations Unit, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA., Mu J; Department of Biostatistics, The Emes Company, LLC, Rockville, Maryland, USA., Makowski M; Department of Biostatistics, The Emes Company, LLC, Rockville, Maryland, USA., Makhene MK; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Nayak SU; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Roberts PC; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Biostatistics, School of Public Health, University of Washington, Seattle, Washington, USA. |
| Corporate Authors: | Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2025 Feb 05; Vol. 80 (1), pp. 223-227. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciae465 |
